drugset / Trial / NCT06955325
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
Phase 3
Not yet recruiting
270 enrolled
The First Affiliated Hospital of Guangzhou Medical University
RandomizedParallel-groupOpen-labelTreatment
Summary
This study explores how adjuvant therapy affects survival in completely resected high-risk stage IA-IB NSCLC patients with different driver gene mutations.
Timeline
- Start
- 2025-05
- Primary completion
- 2030-12
- Completion
- 2035-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Ensartinib | Small molecule | 225 mg | Oral |
| Subject | Icotinib | Small molecule | 125 mg | Oral |
| Subject | rezivertinib | Small molecule | 100 mg | Oral |